Calithera Biosciences (CALA) Raised to Strong-Buy at ValuEngine

Calithera Biosciences (NASDAQ:CALA) was upgraded by stock analysts at ValuEngine from a “buy” rating to a “strong-buy” rating in a report issued on Friday, ValuEngine reports.

CALA stock opened at $5.64 on Friday. The company has a market capitalization of $221.31 million, a price-to-earnings ratio of -3.79 and a beta of 2.21. The company has a debt-to-equity ratio of 0.08, a current ratio of 6.75 and a quick ratio of 6.75. Calithera Biosciences has a one year low of $3.55 and a one year high of $6.90.

Calithera Biosciences (NASDAQ:CALA) last released its earnings results on Thursday, May 9th. The biotechnology company reported ($0.61) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by ($0.18). As a group, sell-side analysts expect that Calithera Biosciences will post -2.06 EPS for the current year.

Hedge funds have recently added to or reduced their stakes in the business. Oxford Asset Management LLP raised its stake in shares of Calithera Biosciences by 135.6% in the 1st quarter. Oxford Asset Management LLP now owns 229,158 shares of the biotechnology company’s stock valued at $1,545,000 after purchasing an additional 131,880 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Calithera Biosciences by 17.5% in the 1st quarter. Geode Capital Management LLC now owns 409,601 shares of the biotechnology company’s stock valued at $2,760,000 after purchasing an additional 60,934 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Calithera Biosciences by 9.1% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 77,304 shares of the biotechnology company’s stock valued at $522,000 after purchasing an additional 6,479 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of Calithera Biosciences by 89.0% in the 1st quarter. Renaissance Technologies LLC now owns 490,198 shares of the biotechnology company’s stock valued at $3,304,000 after purchasing an additional 230,900 shares in the last quarter. Finally, ClariVest Asset Management LLC raised its stake in shares of Calithera Biosciences by 28.5% in the 1st quarter. ClariVest Asset Management LLC now owns 66,800 shares of the biotechnology company’s stock valued at $450,000 after purchasing an additional 14,800 shares in the last quarter. 55.46% of the stock is owned by hedge funds and other institutional investors.

Calithera Biosciences Company Profile

Calithera Biosciences, Inc, a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors.

Further Reading: What is the Rule of 72?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit